Notable Friday Option Activity: RPD, HCA, KTOS

HCA Healthcare saw 4,344 option contracts trade (≈434,400 underlying shares), about 41.5% of its one‑month average daily volume (1.0M shares), led by 2,405 contracts in the $430 put expiring Feb 20, 2026 (≈240,500 shares). Kratos Defense recorded 13,906 option contracts (≈1.4M underlying shares), ~41.4% of its one‑month ADV (3.4M shares), with elevated activity in the $124 call expiring Jan 16, 2026 (806 contracts, ≈80,600 shares). The concentrated strike/expiry flows may signal sizable directional bets or hedging interest and are notable relative to each name's liquidity.

Analysis

Market structure: The concentrated flow — ~434,400 HCA shares (41.5% ADTV) in puts at the $430 Feb‑20‑2026 strike and ~1.4M KTOS shares (41.4% ADTV) in calls — signals institutional directional or hedging activity that can move short‑to‑mid term implied volatility and the underlying. Winners: options sellers collecting premium if flows are hedges; tactical buyers of KTOS calls benefit if defense contract/tailwinds materialize; HCA equity holders are exposed if the put flow is directional. Supply/demand: heavy put demand for HCA implies skewed downside demand (supply of insurance scarce), while call demand in KTOS suggests concentrated bullish positioning — both increase IV skew and bid/offer spreads.

Risk assessment: Tail risks include adverse Medicare/Medicaid reimbursement or hospital regulatory action hitting HCA (medium probability, high impact) and a defense budget pause or contract loss hitting KTOS (lower probability but binary). Immediate (days) risk: IV spikes and gamma from option hedging; short‑term (weeks/months): position unwinds or earnings/contract announcements; long‑term (quarters): fundamentals reassert. Hidden dependency: large block flow may be delta‑hedged structures (not pure directional) that will reverse if rates/yields or correlation moves; catalyst list: HCA earnings/Medicare guidance, KTOS contract wins, Jan–Feb 2026 roll activity and U.S. budget votes.

Trade implications: Direct plays: express bullish KTOS via defined‑risk Jan‑2026 call spread to capture upside while limiting IV decay; protect HCA exposure via Feb‑2026 put spreads rather than naked longs. Pair trade: long KTOS call spread vs short small allocation to a large‑cap healthcare ETF (e.g., XLV) to neutralize beta and isolate sector rotation. Cross‑asset: monitor 10y yield moves >25bp which materially raise healthcare discount rates and stress HCA.

Contrarian angles: Consensus may be misreading hedging for directional selling — if puts are structured‑product buys, dealers will delta hedge by selling stock into weakness then unwind, creating mean reversion once flows stop. The trade may be overdone if IV is rich; a fade on large option‑flow days (sell premium via spreads) could be profitable. Historical parallels: concentrated options flow ahead of fiscal year‑end often unwinds in 2–6 weeks; unexpected contract awards or reimbursement guidance can flip sentiment quickly.

Key Decisions for Investors

• Establish a tactical long KTOS defined‑risk position: buy Jan‑16‑2026 110/140 call spread (1:1) sized to 1–2% portfolio risk; target 2.0–3.0x return if KTOS >124 by Jan expiry, stop‑loss at 50% premium loss or if KTOS <100 on 5‑day close.
• Hedge or express limited bearish on HCA: buy Feb‑20‑2026 430/400 put spread sized to 1% portfolio notional (max loss = premium); widen to 430/380 only if IV compresses >20% relative to pre‑flow level within 10 trading days.
• Relative play: go long KTOS call spread (as above) and short 0.5–1.0% notional of XLV (or HCA stock if already overweight) to isolate defense upside vs healthcare macro sensitivity; rebalancing trigger: rotate if spread P/L exceeds 50% gain or 30% loss.
• Volatility arb / premium capture: if HCA Feb‑2026 $430 put IV rises >25% vs 60‑day ATM IV, sell a defined‑risk put spread closer to mid IV (e.g., sell 430/410) for 0.5–1% portfolio exposure, but limit to 0.5% size and monitor 10y yield movement (>25bp) which mandates flattening the trade.